Navigation Links
Terry Fox Research Institute aims to change diagnosis and management of ovarian cancer worldwide
Date:10/13/2011

MONTREAL, QUE. -- Women throughout the world will benefit from a new, pan-Canadian Terry Fox Research Institute (TFRI) initiative that aims to change the way in which ovarian cancer is diagnosed and managed. TFRI and the Canadian Partnership Against Cancer are providing a total of $5-million in funding for a five-year, multi-site Ovarian Cancer Pan-Canadian Program called COEUR. The program will identify new biomarkers to predict and treat this relatively rare but deadly form of cancer, which will result in the use and application of current and new drugs more effectively for patients.

Ovarian cancer is the fifth-leading cause of cancer-related deaths in the Western world. One in every four women diagnosed with this form of cancer is resistant to standard first-line chemotherapy. Through TFRI, leading ovarian cancer researchers and clinicians across Canada have joined forces to develop a "made-in-Canada solution" to this global clinical problem facing cancer doctors.

The team's work will result in a new stratification system for ovarian carcinoma subtypes and will help clinicians better determine what treatment will work best for each patient. Patients who do not respond to standard therapy can be directed to clinical trials where new therapies are being validated.

"This project will change the way in which pathologists, physicians and clinicians think about ovarian cancer. It will help us to classify and sub-divide ovarian cancer into different diseases through molecular profiling. A better understanding of the disease will enable the development and delivery of more personalized care for the patient, which is both better and more efficacious," says TFRI President and Scientific Director Dr. Victor Ling.

"The program brings together expertise and resources from across the country to improve the lives of women in Canada and beyond who are diagnosed with ovarian cancer," says Dr. Stuart Edmonds, Director of the Research Portfolio at the Canadian Partnership Against Cancer, a national organization funded by Health Canada to lead the implementation of a co-ordinated cancer strategy. "This is one of several projects the Partnership is supporting with the practical goal of identifying emerging technologies that can improve the early detection and treatment of cancer and lead to better outcomes."

Momentum to form the consortium of 35 investigators came from within the ovarian cancer community. The project is headed up by three Canadian researchers at two prominent cancer care and research centres. At the University of Montreal Hospital Research Centre (CRCHUM*), molecular oncologist Dr. Anne-Marie Mes-Masson and gynecologist oncologist Dr. Diane Provencher are the principal investigators. Dr. David Huntsman, a genetic pathologist with the Ovarian Cancer Research Program at BC Cancer Agency and Vancouver Coastal Health, will co-lead the study from Vancouver.

"Ovarian cancer is a relatively rare disease that is also very complex. Today we know that it consists of several different subtypes; these are not yet well understood and we have significantly more work ahead to determine what treatment will work for patients and their specific tumour subtype," says Dr. Huntsman. "This program includes an important knowledge transfer component that will enable the results to be rapidly deployed within the Canadian pathology community and readily translated into practice."

"The women who are participating in this initiative by providing tissue samples for collection and analysis are hoping this research will accelerate the pace of discovery and validation of new biomarkers for ovarian cancer," says Dr. Provencher. "We hope to redirect women to new clinical trials and, in particular, those women who don't respond to first-line therapy."

"The team is building a unique, central scientific platform that will create a rich clinical resource for researchers to validate new biomarkers and treatments for ovarian cancer. By linking together laboratory scientists with the oncologists, surgeons and pathologists who work with the patients on the front lines, our work will be much more relevant and bear fruit that will reach patients much more quickly," says Dr. Mes-Masson. A strength of the program is the ability to link research results across multiple studies underway across the country.
'/>"/>

Contact: Kelly Curwin
kcurwin@tfri.ca
778-237-8158
Terry Fox Research Institute
Source:Eurekalert

Related medicine news :

1. Nevada Qui Tam Attorney Tim Terry to Address Sacramento Gold Rush Chapter of the National Contract Management Association (NCMA)
2. QHR'S Terry Peeples Named 2010 Grassroots Champion by American Hospital Association
3. Great Salt Lake Chapter of National Contract Management Association Hosts Presentation on False Claims Act by Qui Tam Attorney Tim Terry
4. East Tennessee Attorney Brack Terry Obtains $120,000 Jury Award For Injured Mail Carrier
5. Qui Tam Attorney Tim Terry to Speak at Phoenix Thunderbird Chapter of the National Contract Management Association (NCMA)
6. Motivational and Inspirational Author Dr. Terry Cole-Whittaker's New Book: "Live Your Bliss: Practices that Produce Happiness and Prosperity"
7. False Claims Act Attorney Tim Terry to Address Arizona Chapter of the Association of Certified Fraud Examiners
8. Embedded Mobile & M2M Device revenues to Rise to Almost $19 Billion Globally by 2014, Says Juniper Research
9. 2010 HSR Impact Award recognizes surgical safety research
10. MSU launches first anti-counterfeiting research program
11. Researchers map all the fragile sites of the yeast Saccharomyces cerevisiaes genome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. ... magazine’s Code Talker Award, an essay contest in which patients and their families pay ... be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
(Date:6/24/2016)... ... , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event ... that have been wounded in battle and their families. Venture Construction Group is a ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
(Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016 /PRNewswire/ ... pulmonary function testing company, is now able to perform sophisticated lung ... ndd Medical Technologies , Inc. Patients are ... labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients like ... any needed testing done in the comfort of her own home. ...
Breaking Medicine Technology: